Considering that selective LXRα activation did not improve cognitive decline or Aβ plaque deposition in APPswePS1ΔE9 mice, our findings suggest that natural and possibly also synthetic LXRβ agonists are attractive options for the treatment of neurodegenerative disorders such as AD. The gene discussed is NR1H3; the disease is Alzheimer disease.